Investment Banking

Brazil Potash Bolsters Advisory Board with Seasoned Agriculture Finance Expert

Brazil Potash Bolsters Advisory Board with Seasoned Agriculture Finance Expert

Brazil Potash strengthens its strategic leadership by appointing Marcelo Lessa, a veteran with extensive international finance experience, to support its critical Autazes Project development and potash production strategy.

April 28, 2025
Lexaria Bioscience Secures $2 Million in Registered Direct Offering

Lexaria Bioscience Secures $2 Million in Registered Direct Offering

Lexaria Bioscience has entered into a definitive agreement to raise $2 million through a registered direct offering of common stock, providing capital for working capital and general corporate purposes.

April 25, 2025
Economic Uncertainty Stalls Investment Banking Recovery in Early 2025

Economic Uncertainty Stalls Investment Banking Recovery in Early 2025

Major U.S. banks report modest investment banking revenues in Q1 2025, reflecting ongoing economic challenges and market volatility that are delaying the sector's anticipated revival.

April 25, 2025
Investment Banking Revival Stalls Amid Economic Uncertainty

Investment Banking Revival Stalls Amid Economic Uncertainty

Major U.S. banks experienced lower-than-expected investment banking revenues in the first quarter of 2025, reflecting broader economic challenges and market volatility that are delaying sector recovery.

April 24, 2025
ROTH Capital Partners Celebrates 25 Years of Community Impact at Annual Conference

ROTH Capital Partners Celebrates 25 Years of Community Impact at Annual Conference

The 37th Annual ROTH Conference in Dana Point, California, marked a significant milestone in the firm's history, highlighting its deep-rooted community connections and commitment to fostering meaningful relationships over the past quarter-century.

April 17, 2025
Stonegate Initiates Coverage on Alpha Cognition, Projects Strong Growth for New Alzheimer's Drug

Stonegate Initiates Coverage on Alpha Cognition, Projects Strong Growth for New Alzheimer's Drug

Alpha Cognition's newly approved Alzheimer's drug ZUNVEYL is positioned to address a significant market gap with a potentially safer treatment option, as Stonegate Capital Partners initiates coverage with a valuation range of $27.62 to $38.44 per share.

February 4, 2025
PreviousPage 7 of 7Next